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Objective: To evaluate the consistency of three commercial scale lots of candidate herpes simplex virus
(HSV) type 2 (HSV-2) vaccine in adolescent girls.
Methods: A total of 554 healthy girls aged 10–17 years, from Belgium, Canada, and United States, were
enrolled and randomized to receive one of the three manufacturing lots of the candidate glycoprotein
D2 vaccine (gD2-AS04, GlaxoSmithKline Vaccines) according to a 0, 1 and 6-month schedule. Consistency
was based on anti-gD geometric mean titers (GMTs) 1 month post-dose 3 among HSV seronegative sub-
jects complying to study procedures (N = 312): two-sided 90% conﬁdence interval (CI) for the GMT ratio
between each pair of vaccine lots had to be within the [0.67; 1.5] consistency interval.
Results: Pre-speciﬁed consistency criteria were reached. At month 2 (1 month after the second vaccine
dose) anti-gD antibodies were detected in all study participants, while the proportion of subjects with
HSV-2 neutralizing antibodies ranged from 93% to 96.2%, remaining >90% throughout the study (between
93.7% and 96.1% for the three vaccine lot groups at month 12). The three vaccine lots had similar reac-
togenicity proﬁles. The incidence of grade 3 solicited or unsolicited adverse events (AEs) ranged from
17.9% to 22.2% of subjects.
Conclusions: This study demonstrated the lot-to-lot consistency of three commercial scale production
lots of herpes simplex candidate vaccine. The vaccine was immunogenic and had a clinically acceptable
safety proﬁle when administered in HSV type 1 and HSV-2 seronegative girls aged 10–17 years. The study
was registered at clinicaltrials.gov (identiﬁer NCT00224471).
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Herpes virus type 2 (HSV-2) infection is one of the most com-
mon sexually transmitted diseases, with a reported seropreva-
lence varying considerably among different populations and age
groups [1,2]. A systematic review of the literature estimated that
in 2003 there were 536 million persons 15–49 years old whowere HSV-2 seropositive, accounting for 16% of the world’s
population in this age group [1]. Estimated prevalence varied by
geographical region: in Western Europe, HSV-2 infection was re-
ported in 18% of women and 13% of men [1,3], while in countries
from Sub-Saharan Africa up to 70% of women and 55% of men
were infected [1,4]. In the US, the National Health and Nutrition
Examination survey reported a 30% increase in HSV-2 seropreva-
lence between the periods 1976–1980 and 1988–1994 [5]; HSV-2
seroprevalence then decreased to an estimated 17% during the
period 1999–2004 [6], and remained relatively stable between
2005 and 2008 [7].
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immunodeﬁciency virus (HIV) and HSV-2 infection [8,9]. Although
initially considered to be an opportunistic infection, it is now ac-
cepted that HSV-2 potentiates the risk of HIV acquisition and
transmission [10]. The results of a meta-analysis of 19 longitudinal
studies showed that HSV-2 seropositivity increased the risk of
acquiring HIV infection 3-fold [10].
HSV infection in women of reproductive age is associated with
the risk of viral transmission frommother to the neonate [11], with
potential consequences of spontaneous abortion, intrauterine
growth retardation, preterm delivery, intrauterine or postnatal
death or severe neurodevelopmental disabilities [11,12]. HSV
transmission can occur in utero (ascending infection or transplac-
entary due to maternal viremia HSV infection), during delivery
(85–90% of neonatal HSV infections) or postnatally [11,12]. The
risk of transmission is higher in women with primary infection
during pregnancy than in women with recurrent infection [13].
High prevalence and the potential social and psychological im-
pact of genital herpes infection have stimulated interest in the
development of a vaccine to prevent infection or disease. With
the incidence of HSV-2 doubling between the age groups 12–19
and 20–29 years [14], female adolescents represent a target popu-
lation for potential HSV-2 vaccines.
The prophylactic candidate vaccine developed by GlaxoSmithK-
line Vaccines is an aluminum hydroxide and 3-O-deacylated
monophosphoryl HSV-2 gD-based subunit vaccine formulated in
adjuvant system (AS04), lipid A (MPL). HSV-2 gD is obtained from
Chinese hamster ovary cells transfected with a gene encoding a
truncated form of gD from the HSV-2 strain G [15]. The immunoge-
nicity and safety of this candidate vaccine have been previously as-
sessed in clinical trials [15,16]. However, most of these studies
were conducted in adults.
Clinical evaluations to conﬁrm the manufacturing consistency
of consecutively produced lots of vaccine intended for commercial
use are prerequisites for licensure [17,18]. The aim of these trials is
to conﬁrm the reliability of the manufacturing process following
transition from small-scale to full-scale production. The study re-
ported here was designed to evaluate the consistency of three
commercial scale lots of the candidate HSV-2 vaccine in HSV type
1 (HSV-1) and HSV-2 seronegative girls aged 10–17 years.2. Methods
2.1. Study objectives
The primary objective of this trial was to demonstrate, 1 month
following the third dose, the lot-to-lot consistency of three differ-
ent commercial scale production lots of herpes simplex candidate
vaccine gD2-AS04 as determined by GMTs of antibodies against
HSV gD (anti-gD) 1 month post dose 3.
Secondary objectives were to evaluate the immune response
rate based on anti-gD and anti-HSV neutralizing antibody re-
sponses and to describe safety and reactogenicity of the HSV can-
didate vaccine in all treatment groups.2.2. Study design and participants
This was a phase III, multicenter, double-blind, randomized
study, with three parallel treatment groups (registered at
www.ClinicalTrials.gov: NCT00224471).
It was conducted at 13 study centers in three countries
(Belgium, Canada, and United States) and aimed to enroll 522
healthy HSV-1 and HSV-2 seronegative girls at initial screening
who were 10–17 years of age at the time of ﬁrst vaccination.
Exclusion criteria included: pregnancy (urine pregnancy test orlactation; any previous history, or current clinical signs or symp-
toms of oro-labial, genital or non-genital HSV disease; previous
vaccination against herpes; previous administration of MPL
adjuvant; any conﬁrmed or suspected immunosuppressive or
immunodeﬁcient condition; history of allergic disease or reactions
likely to be exacerbated by any component of the study vaccines. If
the participant was of childbearing potential, she was asked to be
abstinent or use an effective method of birth control for 30 days
prior to vaccination and agreed to continue such precautions for
2 months after completion of the vaccination series.
Enrollment began on February 3, 2004. Participants were strat-
iﬁed into two age groups, 10–15 years and 16–17 years, ensuring
that no more than 50% and no fewer than 25% of subjects were
in the 16–17 years age stratum. Enrolled subjects were random-
ized using a central randomization system on the Internet accord-
ing to a balanced allocation (1:1:1) to receive one of three lots of
the candidate gD2-AS04 vaccine. The randomization algorithm
was based on minimization accounting for center and age stratum
with equal weight. Each participant was followed for 12 months
with visits at months 0, 1, 2, 6, 7 and 12. At each visit, participants
were provided individual, age-appropriate counseling on preg-
nancy prevention and methods to reduce risk of sexually transmit-
ted infections.
The study protocol and all study-related documents were ap-
proved by the national, regional, or investigational center Indepen-
dent Ethics Committee or Institutional Review Board. Written
informed consent or assent was provided by all participants prior
to the performance of any study-speciﬁc procedures.
2.3. Study vaccines
The vaccine used in this study was developed and manufac-
tured by GlaxoSmithKline [15,16,19]. It contained 20 lg of trun-
cated glycoprotein D from HSV-2 strain G and the AS04 adjuvant
system comprising 50 lg of MPL, and 0.5 mg of aluminum
hydroxide.
Participants were randomly allocated to receive one of three
manufacturing lots of the vaccine as follows: AHS1020A2 (group
A), AHS1021A2 (group B) and AHS1022A2 (group C). The study
vaccine was administered intramuscularly in the deltoid region
of the non-dominant arm according to a 0, 1 and 6 months
schedule.
2.4. Immunogenicity evaluation
Initial screening for HSV serostatus was performed to determine
eligibility for entry into the study, using both the HSV non-type
speciﬁc Enzygnost anti-HSV IgG enzyme-linked immunosorbent
assay (ELISA) (Behring) and the HSV-2 type speciﬁc HerpeSelect-
2™ ELISA (Focus Technologies). All participants determined to be
seronegative by these two ELISA assays were considered eligible
and were included in the total vaccinated cohort (TVC). Partici-
pants’ serostatus was later conﬁrmed by Western blot (University
of Washington, Seattle, WA) [20] on all serum samples collected at
study entry and by an anti-gD in-house ELISA (described below) on
serum samples collected at time of randomization (month 0) for all
participants included in the TVC. A participant was considered HSV
seropositive byWestern blot if two of three bands (for glycoprotein
B, virion polypeptide 5, and infected cell protein-35) were visual-
ized. The conﬁrmed results of participants’ serostatus were not
available at the time of randomization. Participants seropositive
by Western blot or anti-gD in-house ELISA before vaccination were
excluded from the according-to-protocol (ATP) cohort.
Anti-gD and anti-HSV neutralizing antibody titers were mea-
sured in serum samples for all subjects at months 0, 2, 7 and 12
in a central laboratory. The anti-gD in-house ELISA was performed
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ously diluted in phosphate buffered saline to give a concentration
of 2.5 lg/ml. Subsequently participant’s sera were added to the
plate and allowed to incubate for 2 h at 18–22 C. After washing
ﬁve times with NaCl Tween (Merck) 0.05% buffer, the presence of
anti-gD antibodies was revealed by addition of an anti-human con-
jugate. Human control sera with known titers were included in
each assay for validation of the results. Anti-gD antibody titers
were expressed in ELISA units (EU)/ml, with reference to a stan-
dard serum, using the 4-parameter method [21]. The assay cut-
off titer was based on the evaluation of 110 sera samples from
healthy subjects enrolled in another HSV study that tested sero-
negative for IgM and IgG antibodies against HSV using two kits
from Behring. The cut-off had to be higher than the range of test
results for these sera and the lowest limit of quantitation. The low-
est limit of quantitation was established by multiplying the lowest
dilution of the test by the concentration corresponding to 10% opti-
cal density and calculating the values from 100 different standard
curves. The results obtained for the control sera ranged from 0 to
31 EU/ml and the lowest limit of quantitation was 30 EU/ml (stan-
dard deviation: 7 EU/ml). Based on these data, the cut-off for the
in-house ELISA used to determine the anti-gD antibody titers was
set at 40 EU/ml. Participants with titers P40 EU/ml were consid-
ered seropositive [16]. Anti-HSV neutralizing antibody titers were
assessed using an in-house water-soluble tetrazolium salt
(WST-1)-based colorimetric assay [22,23]. Serially diluted sera
from participants were incubated with HSV-2 virus particles and
complement for 2 h at 37 C in 96-well plates before adding a Vero
cell suspension. After a 6-day incubation period at 37 C in the
presence of 5% CO2 in air, the culture medium was removed and
cell viability was determined by measuring the optical density at
k = 450 nm. The assay cut-off was set at 4 arbitrary units based
on the estimated dose at which 90% of the virus is neutralized
(ED90). Seropositivity rates and GMTs, with 95% CI, were calcu-
lated for anti-gD antibodies and anti-HSV neutralising antibodies
by group at all time points for which blood samples were taken.
2.5. Safety evaluation
Safety was assessed through self-reporting of solicited AEs (on
the day of vaccination and 6 days following each dose), unsolicited
AEs (occurring within 30 days after each dose, reported by investi-
gator). Serious adverse events (SAEs), new onset chronic diseases
(NOCD), other medically signiﬁcant conditions and conditions
prompting emergency room (ER) visits or physician visits that
were not related to common diseases were recorded in all subjects
throughout the entire study period, regardless of causal relation-
ship to vaccination or intensity.
2.6. Statistical analysis
The primary endpoint was anti-gD antibody titer assessed at
month 7 in the ATP cohort. The ATP cohort included subjects vac-
cinated with three doses as per protocol, who were conﬁrmed to be
HSV seronegative pre-vaccination by both Western blot and anti-
gD in-house ELISA assay and who had immunogenicity results
available post dose 3. Consistency analysis was based on the
two-sided 90% CI for the GMT ratio between each pair of gD2-
AS04 vaccine lots and was demonstrated if the lower and upper
limits of the 90% CI were within the [0.67;1.5] consistency interval.
The GMT group ratios were derived from group comparison in a
one way ANOVA model on log-transformed titer. To be consistent
with the industry post-hoc standards for consistency, the 95% CIs
for the month 7 anti-gD GMT ratios were also computed between
each pair of gD2-AS04 vaccine lots using an ANOVA model that in-
cluded vaccine group (each group), age (615 years, >15 years atdose 1) and Western blot status at pre-vaccination (HSV 1-/2-:
yes/no) as co-variables. The study was not statistically powered
for this analysis because it was not planned per protocol.
Secondary endpoints were: anti-gD antibody titer at months 2
and 12; anti-HSV neutralizing antibody titers at months 2, 7 and
12; occurrence of solicited (day 0–6) and unsolicited symptoms
(day 0–29); occurrence of NOCD, other medically signiﬁcant condi-
tions or SAEs throughout the entire study period. All local injection
site symptoms (solicited or unsolicited) were considered related to
vaccination.
With respect to the descriptive analysis of immunogenicity, the
percentages of subjects with anti-gD and anti-HSV neutralizing
antibody titers at or above the pre-deﬁned cut-off values were tab-
ulated with exact 95% CIs [24] and GMTs were tabulated with 95%
CIs for anti-gD and anti-HSV neutralizing antibody titers, respec-
tively. With respect to the descriptive analysis of safety, the per-
centage of subjects reporting safety endpoints was provided with
exact 95% CI. These analyses were also performed by age (10–
15 years old and 16–17 years old) and by weight (655 kg and
>55 kg), for the three gD2-AS04 lots pooled.
The sample size of 146 subjects per lot in the ATP cohort was
targeted to reach at least 90% power for meeting simultaneously
the consistency criteria for the three pairwise lot comparisons.
The sample size was based on three equivalence tests with 5% al-
pha under the alternative hypothesis that the three lots were iden-
tical with a population standard error for a log10 transformed titer
of 0.384. The study was not powered to be analyzed with 95% CI,
i.e. 2.5% alpha. Assuming a rate of non-evaluable participants of
20%, 522 participants were planned to be enrolled in this study,
with 184 participants in each study group.3. Results
3.1. Study population
A total of 554 participants were enrolled and randomized. All
participants received at least one dose of study vaccine and were
included in the total vaccinated cohort (TVC) (Fig. 1). Twelve par-
ticipants withdrew from the study prematurely: 4 were lost to fol-
low-up, 3 withdrew consent and 5 moved from the study area. 542
participants (97.8% of the TVC) completed the study.
The ATP cohort for immunogenicity included 312 participants
who were negative for both HSV-1 and HSV-2 antibodies by Wes-
tern blot and anti-gD in-house ELISA. 242 participants were elim-
inated from the ATP cohort for immunogenicity due to
noncompliance with study eligibility criteria (initially seropositive
or unknown serostatus), noncompliance with vaccination or blood
sampling schedule, or missing serological data (Fig. 1). No partici-
pants prematurely discontinued from the study due to AEs.
The mean age in the three treatment groups ranged from 14.2 to
14.4 years; 87.5% of the study participants were White/Caucasian
(Table 1). At the time of the ﬁrst dose, the majority of participants
in each group were negative for both HSV-1 and HSV-2 antibodies
by Western blot (ranging from 79.9% to 83.8% across the three
groups). Approximately 10% of participants were positive for
HSV-1 and negative for HSV-2 by Western blot (ranging from
9.2% to 12.4% across the three groups).3.1. Immunogenicity
The protocol-deﬁned criteria for lot-to-lot consistency at month
7 (1 month after the third dose) were met (primary objective) (Ta-
ble 2). The two-sided 90% CI of the anti-gD GMT ratio for each pair
of groups was within the pre-deﬁned range [0.67; 1.5], thus dem-
onstrating lot-to-lot consistency.
554 patients enrolled, randomized and 
vaccinated (TVC) 
Group A 
(N=185) 
155 N1N2 
17 P1N2 
13 other 
181 completed the study 
4 participants withdrawn 
− 2 lost to follow-up 
− 1 consent withdrawal 
− 1 moved from study 
area 
Group B 
(N=184) 
147 N1N2 
18 P1N2 
19 other 
Group C 
(N=185) 
148 N1N2 
23 P1N2 
14 other 
177 completed the study 
7 participants withdrawn 
− 2 lost to follow-up 
− 2 consent 
withdrawal 
− 3 moved from study 
area 
184 completed the study 
1 participant withdrawn 
− moved from study 
area 
ATP cohort for 
immunogenicity 
(N = 104) 
81 participants excluded (6 due 
to administration of vaccines 
forbidden; 29 due to 
noncompliance with study 
eligibility criteria; 31 initially 
seropositive or unknown 
antibody status*; 10 due to 
noncompliance with the 
vaccination schedule; 4 due to 
noncompliance with the blood 
sampling schedule; 1 with 
essential serological data 
missing) 
ATP cohort for 
immunogenicity 
(N = 101) 
83 participants excluded (3 due 
to administration of vaccines 
forbidden; 36 due to 
noncompliance with study 
eligibility criteria; 23 initially 
seropositive or unknown 
antibody status*; 18 due to 
noncompliance with the 
vaccination schedule; 1 due to 
noncompliance with the blood 
sampling schedule; 1 with 
essential serological data 
missing; 1 other reason) 
ATP cohort for 
immunogenicity 
(N = 107) 
78 participants excluded (2 due 
to administration of vaccines 
forbidden; 37 due to 
noncompliance with study 
eligibility criteria; 21 initially 
seropositive or unknown 
antibody status*; 15 due to 
noncompliance with the 
vaccination schedule; 1 due to 
noncompliance with the blood 
sampling schedule; 1 with 
essential serological data 
missing; 1 other reason) 
Fig. 1. Study ﬂow chart. Group A = gD2-AS04 vaccine lot AHS1020A2; Group B = gD2-AS04 vaccine lot AHS1021A2; Group C = gD2-AS04 vaccine lot AHS1022A2; N = number
of subjects; TVC = total vaccinated cohort; ATP = according to protocol; N1N2 = negative for HSV-1 and negative for HSV-2 by Western blot; P1N1 = positive for HSV-1 and
negative for HSV-2 by Western blot; ⁄Not conﬁrmed seronegative by both Western blot and anti-gD in-house ELISA.
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dard, namely two-sided 95% CIs, all but one pair of lots led to CI
within the [0.67; 1.5] interval; for the comparison of group B with
group C, the 95% CI of the age-adjusted ratio (B over C) was [0.66;
0.96]. As explained, this post-hoc consistency criterion was not
planned and therefore the study was not powered for this analysis.
When the analysis was repeated on a larger sample also including
82 participants, who were seronegative by ELISA but whose pre-
vaccination HSV serostatus was not conﬁrmed by Western blot,
the two-sided 95% CIs for each comparison were within the
[0.67; 1.5] interval.
3.1.1. HSV glycoprotein D speciﬁc antibodies (Fig. 2)
All subjects in the three vaccine lot groups, irrespective of age,
weight or menarcheal status, were seropositive for anti-gD after
the second dose and remained so through month 12 (approxi-
mately 6 months after the third dose). Between month 2 and
month 7, anti-gD GMTs levels increased 1.7–2.1-fold in all vaccine
lot groups. Levels then decreased 3.6–3.9-fold by month 12.
Descriptive analysis of the anti-gD response over the course of
the study showed higher antibody responses in the younger age
stratum than the older age stratum and in the 655 kg stratum thanthe >55 kg stratum at each post-vaccination time point. GMT ratios
of the 10–15 year age group over the 16–17 year age group were:
1.4 at month 2, 1.2 at month 7 and 1.0 at month 12. When GMTs
in the 655 kg and >55 kg groups were compared, the ratios were
as follows: 1.5 at month 2, 1.2 at month 7 and 1.2 at month 12.
3.1.2. HSV neutralizing antibodies (Fig. 2)
At month 2 (1 month after the second vaccine dose), anti-HSV
seropositivity rates for neutralizing antibodies ranged from 93%
(group A) to 96.2% (group C) and remained >90% throughout the
study duration (ranging from 93.7% to 96.1% across the three vac-
cine lot groups at month 12).
GMTs for anti-HSV neutralizing antibodies displayed similar ki-
netic proﬁles in all the vaccine lot groups through the course of the
study. From pre-vaccination to 1 month post dose 2, anti-HSV
GMTs increased in all groups, with values ranging from 16.6 ED90
in group A to 21.7 ED90 in group C. GMTs reached peak levels at
month 7, 1 month after the third vaccine dose. Between month 2
and month 7, anti-HSV GMTs increased 3.9-fold in group A
(GMT = 16.6 ED90 and 65.1 ED90 at month 2 and month 7, respec-
tively), 3.2-fold in group B (GMT = 19.4 ED90 at month 2 and
62.6 ED90 at month 7) and 3.5-fold in group C (GMT = 21.7 ED90
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Fig. 2. Geometric mean titers for gD speciﬁc antibodies (panel A) and HSV neutralizing antibodies (panel B). Group A = gD2-AS04 vaccine lot AHS1020A2; Group B = gD2-
AS04 vaccine lot AHS1021A2; Group C = gD2-AS04 vaccine lot AHS1022A2; GMT = geometric mean antibody titer.
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GMT values decreased between 3.6- and 3.8-fold in all three vac-
cine lot groups, but remained higher than the baseline levels.
Data were also analyzed by age groups and weight for the three
lots pooled. One month after the second dose, seropositivity rates
were 98% in the 655 kg group and 92% in the >55 kg group,
increasing to 99.4% and 98.7% after the third dose. At all time
points, anti-HSV GMTs were higher in the 655 kg group than in
the >55 kg group. GMT ratios for the two weight groups (655 kg
and >55 kg) were as follows: 1.3 at month 2, 1.0 at month 7 and
1.1 at month 12. By age stratum, seropositivity rates after the sec-
ond dose were 93.6% in 16–17 year olds and 95.9% in 10–15 year
olds, increasing to 98.5% and 100% after the third dose. Seropositiv-
ity rates remained >90% at month 12 irrespective of age.3.2. Safety and reactogenicity
Overall, the percentage of subjects reporting at least one symp-
tom after all doses (solicited or unsolicited, local or general) ranged
from 95.7% to 96.7%. At least one AE (solicited or unsolicited) was
reported for 95.7% to 96.7% of subjects. Overall, the incidence ofgrade 3 AEs (solicited or unsolicited) ranged from 17.9% to 22.2%
(Supplementary Table). The incidence of grade 3 AEs considered
by the investigator to be related to study vaccine was 15.7% in
group A, 15.8% in group B and 17.3% in group C.3.2.1. Solicited adverse events (Table 3)
Injection site pain was the most frequently reported solicited
local symptom after each vaccine dose in all three vaccine lot
groups (reported by 91.4%, 91.8% and 89.2% of participants in
groups A, B and C, respectively). At least 7.6% of participants in
each group reported grade 3 injection site pain after vaccine
administration.
The most frequently reported solicited general symptoms were
fatigue (reported by 35.7%, 47.3% and 49.7% of participants in
groups A, B and C, respectively) and headache (reported by
41.1%, 48.4% and 53.5% of participant in groups A, B and C, respec-
tively). The most commonly reported grade 3 solicited general
symptoms per group were fatigue in group A (2.2% of subjects), fa-
tigue and headache in group B (both reported in 3.3% of subjects)
and malaise in group C (7.0% of subjects). Fever (deﬁned as oral
Table 1
Demographic characteristics of vaccinated participants (total vaccinated cohort).
Characteristics Total N = 554 Group A N = 185 Group B N = 184 Group C N = 185
Age (years)
Mean ± SD 14.3 ± 2.1 14.2 ± 2.2 14.3 ± 2.1 14.4 ± 2.1
Median 15.0 15.0 14.0 15.0
Range (min–max) 10–17 10–17 10–17 10–17
BMI (kg/m2)
Mean ± SD 21.7 ± 4.2 22.1 ± 4.5 21.4 ± 4.4 21.5 ± 3.8
Median 20.9 20.9 20.7 20.9
Race, n (%)
White/Caucasian 485 (87.5) 160 (86.5) 157 (85.3) 168 (90.8)
Black 25(4.5) 10 (5.4) 7 (3.8) 8 (4.3)
East/South East Asian 9 (1.6) 3 (1.6) 6 (3.3) 0 (0.0)
South Asian 5 (0.9) 3 (1.6) 2 (1.1) 0 (0.0)
American Hispanic 15 (2.7) 6 (3.2) 3 (1.6) 6 (3.2)
Other 15 (2.7) 3 (1.6) 9 (4.9) 3 (1.6)
Menarcheal status at baseline, n (%)
Pre-menarcheal 112 (20.2) 39 (21.1) 32 (17.4) 41 (22.2)
Post-menarcheal 442 (79.8) 146 (78.9) 152 (82.6) 144 (77.8)
Western blot at baseline, n (%)
N1N2 450 (81.2) 155 (83.8) 147 (79.9) 148 (80.0)
P1N2 58 (10.5) 17 (9.2) 18 (9.8) 23 (12.4)
other 46 (8.3) 13 (7.0) 19 (10.3) 14 (7.6)
Group A = subjects receiving gD2-AS04 vaccine lot AHS1020A2.
Group B = subjects receiving gD2-AS04 vaccine lot AHS1021A2.
Group C = subjects receiving gD2-AS04 vaccine lot AHS1022A2.
N = number of subjects; n/% = number/percentage of subjects in a given category; SD = standard deviation; N1N2 = negative for HSV-1 and negative for HSV-2; P1N2 = po-
sitive for HSV-1 and negative for HSV-2.
Table 2
Ratios of post-vaccination anti-gD GMT at month 7 between the three gD2-AS04 vaccine lots (according to protocol cohort for immunogenicity).
ATP cohort for immunogenicity GMT ratio
Group N GMT Group N GMT Ratio order Value (90% CI)
Group A 104 9012.6 Group B 99 8233.6 Group A/Group B 1.09 (0.94–1.28)
Group A 104 9012.6 Group C 106 10,417.6 Group A/Group C 0.87 (0.74–1.01)
Group B 99 8233.6 Group C 106 10,417.6 Group B/Group C 0.79 (0.68–0.92)
ATP cohort for immunogenicity Adjusted GMT ratio⁄
Group description N Adjusted GMT Group description N Adjusted GMT⁄ Ratio order Value (95% CI)
Group A 104 8833.4 Group B 99 8104.4 Group A/Group B 1.09 (0.90–1.31)
Group A 104 8833.4 Group C 106 10,142.8 Group A/Group C 0.87 (0.72–1.05)
Group B 99 8104.4 Group C 106 10,142.8 Group B/Group C 0.80 (0.66–0.96)
ATP cohort for immunogenicity and subjects excluded because they were not conﬁrmed N1N2 at baseline Adjusted GMT ratio§
Group description N Adjusted GMT Group description N Adjusted GMT§ Ratio order Value (95% CI)
Group A 125 8133.4 Group B 128 7689.7 Group A/Group B 1.06 (0.90–1.25)
Group A 125 8133.4 Group C 138 9586.8 Group A/Group C 0.85 (0.72–1.00)
Group B 128 7689.7 Group C 138 9586.8 Group B/Group C 0.80 (0.68–0.94)
Group A = gD2-AS04 vaccine lot AHS1020A2; Group B = gD2-AS04 vaccine lot AHS1021A2; Group C = gD2-AS04 vaccine lot AHS1022A2.
N = number of subjects with both pre- and post-vaccination results available; GMT = unadjusted geometric mean antibody titer; GMT⁄ = geometric mean antibody titer
adjusted for age strata; GMT§ = geometric mean antibody titer adjusted for age strata and Western blot status (N1N2 Yes/No); N1N2 = negative for HSV-1 and negative for
HSV-2; 95% CI = 95% conﬁdence interval for the adjusted GMT ratio (ANOVA model)
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groups B and C and 12.4% in group A.3.2.2. Unsolicited adverse events (Table 4)
During the 30 days after vaccination, 60.5% participants in
group A, 60.9% in group B and 61.1% in group C reported at least
one unsolicited adverse event. Upper respiratory tract infections
were the most frequently reported unsolicited AE in all treatment
groups, with an incidence of 8.1% in groups A and C and 14.7% in
group B. At least one grade 3 unsolicited AE was reported for
6.3% of participants. The most commonly reported grade 3 unsolic-
ited AE was upper respiratory tract infection, occurring in 5participants overall (0.9%). Unsolicited AEs prompting medical
attention were reported with an incidence ranging from 21.6% in
group A to 24.9% in group C.3.2.3. Serious adverse events and new onset chronic diseases
During the study period, 13 non-fatal SAEs were reported in 13
participants: 2 in group A (1.1%), 5 in group B (2.7%) and 6 in group
C (3.2%). None were considered by the investigator as being related
to vaccination and all resolved.
At least one NOCD was identiﬁed by the investigator in 8.1%,
7.6% and 4.9% of participants in groups A, B and C, respectively.
The most commonly reported NOCD was asthma: 2 subjects in
Table 3
Incidence of solicited local and general symptoms within the 7-day post-vaccination period (total vaccinated cohort)
Lot A Lot B Lot C Total
N = 185 N = 184 N = 185 N = 554
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Local
Pain 169 91.4 (86.3–95.0) 169 91.8 (86.9–95.4) 165 89.2 (83.8–93.3) 503 90.8 (88.1–93.1)
Grade 3 14 7.6 (4.2–12.4) 19 10.3 (6.3–15.7) 22 11.9 (7.6–17.4) 55 9.9 (7.6–12.7)
Redness 66 35.7 (28.8–43.0) 55 29.9 (23.4–37.1) 69 37.3 (30.3–44.7) 190 34.3 (30.3–38.4)
Grade 3a 1 0.5 (0.0–3.0) 1 0.5 (0.0–3.0) 1 0.5 (0.0–3.0) 3 0.5 (0.1–1.6)
Swelling 50 27.0 (20.8–34.0) 49 26.6 (20.4–33.6) 48 25.9 (19.8–32.9) 147 26.5 (22.9–30.4)
Grade 3a 8 4.3 (1.9–8.3) 3 1.6 (0.3–4.7) 3 1.6 (0.3–4.7) 14 2.5 (1.4–4.2)
General
Arthralgia 41 22.2 (16.4–28.8) 42 22.8 (17.0–29.6) 36 19.5 (14.0–25.9) 119 21.5 (18.1–25.1)
Grade 3 3 1.6 (0.3–4.7) 2 1.1 (0.1–3.9) 3 1.6 (0.3–4.7) 8 1.4 (0.6–2.8)
Fatigue 66 35.7 (28.8–43.0) 87 47.3 (39.9–54.8) 92 49.7 (42.3–57.2) 245 44.2 (40.0–48.5)
Grade 3 4 2.2 (0.6–5.4) 6 3.3 (1.2–7.0) 8 4.3 (1.9–8.3) 18 3.2 (1.9–5.1)
Headache 76 41.1 (33.9–48.5) 89 48.4 (41.0–55.8) 99 53.5 (46.0–60.9) 264 47.7 (43.4–51.9)
Grade 3 2 1.1 (0.1–3.9) 6 3.3 (1.2–7.0) 7 3.8 (1.5–7.6) 15 2.7 (1.5–4.4)
Malaise 56 30.3 (23.7–37.4) 57 31.0 (24.4–38.2) 70 37.8 (30.8–45.2) 183 33.0 (29.1–37.1)
Grade 3 3 1.6 (0.3–4.7) 5 2.7 (0.9–6.2) 13 7.0 (3.8–11.7) 21 3.8 (2.4–5.7)
Rash 5 2.7 (0.9–6.2) 13 7.1 (3.8–11.8) 8 4.3 (1.9–8.3) 26 4.7 (3.1–6.8)
Grade 3 0 0.0 (0.0–2.0) 0 0.0 (0.0–2.0) 0 0.0 (0.0–2.0) 0 0.0 (0.0–0.7)
Fever 23 12.4 (8.0–18.1) 21 11.4 (7.2–16.9) 21 11.4 (7.2–16.8) 65 11.7 (9.2–14.7)
Grade 3b 1 0.5 (0.0–3.0) 1 0.5 (0.0–3.0) 1 0.5 (0.0–3.0) 3 0.5 (0.1–1.6)
Urticaria 2 1.1 (0.1–3.9) 2 1.1 (0.1–3.9) 5 2.7 (0.9–6.2) 9 1.6 (0.7–3.1)
Grade 3c 0 0.0 (0.0–2.0) 0 0.0 (0.0–2.0) 0 0.0 (0.0–2.0) 0 0.0 (0.0–0.7)
Group A = gD2-AS04 vaccine lot AHS1020A2; Group B = gD2-AS04 vaccine lot AHS1021A2; Group C = gD2-AS04 vaccine lot AHS1022A2; Total = data from the three treatment
groups pooled; N = number of subjects with available results; n/% = number/percentage of subjects reporting the symptom at least once; 95% CI = 95% conﬁdence interval.
a Grade 3 local injection site redness and swelling was deﬁned as any injection site redness and swelling >30 mm and persisting for more than 24 h, i.e., for two consecutive
days.
b Grade 3 fever was deﬁned as oral temperature >39.0 C.
c Grade 3 urticaria was deﬁned as urticaria distributed on at least four body areas.
All other symptoms were recorded as grade 3 if they prevented normal, everyday activities (in adults/adolescents, such an AE would, for example, prevent attendance at
work/school and would necessitate the administration of corrective therapy).
Table 4
Percentage (%) of participants with unsolicited local and general AEs (P5 cases) within the 30-day post-vaccination period (total vaccinated cohort).
Primary system organ class Group A
N = 185
Group B
N = 184
Group C
N = 185
Total
N = 554
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
At least one symptom 112 60.5 (53.1–67.6) 112 60.9 (53.4–68.0) 113 61.1 (53.7–68.1) 337 60.8 (56.6–64.9)
Abdominal pain 5 2.7 (0.9–6.2) 6 3.3 (1.2–7.0) 6 3.2 (1.2–6.9) 17 3.1 (1.8–4.9)
Diarrhea 3 1.6 (0.3–4.7) 5 2.7 (0.9–6.2) 4 2.2 (0.6–5.4) 12 2.2 (1.1–3.8)
Nausea 9 4.9 (2.2-9.0) 6 3.3 (1.2–7.0) 6 3.2 (1.2–6.9) 21 3.8 (2.4–5.7)
Vomiting 8 4.3 (1.9–8.3) 8 4.3 (1.9–8.4) 9 4.9 (2.2–9.0) 25 4.5 (2.9–6.6)
Inﬂuenza-like illness 5 2.7 (0.9–6.2) 3 1.6 (0.3–4.7) 2 1.1 (0.1–3.9) 10 1.8 (0.9–3.3)
Injection site reaction 1 0.5 (0.0–3.0) 3 1.6 (0.3–4.7) 5 2.7 (0.9–6.2) 9 1.6 (0.7–3.1)
Nasopharyngitis 14 7.6 (4.2–12.4) 11 6.0 (3.0–10.4) 15 8.1 (4.6–13.0) 40 7.2 (5.2–9.7)
Upper respiratory tract infection 15 8.1 (4.6–13.0) 27 14.7 (9.9–20.6) 15 8.1 (4.6–13.0) 57 10.3 (7.9–13.1)
Headache 12 6.5 (3.4–11.1) 18 9.8 (5.9–15.0) 13 7.0 (3.8–11.7) 43 7.8 (5.7–10.3)
Dysmenorrhea 5 2.7 (0.9–6.2) 3 1.6 (0.3–4.7) 4 2.2 (0.6–5.4) 12 2.2 (1.1–3.8)
Cough 1 0.5 (0.0–3.0) 6 3.3 (1.2–7.0) 8 4.3 (1.9–8.3) 15 2.7 (1.5–4.4)
Oropharyngeal pain 12 6.5 (3.4–11.1) 9 4.9 (2.3–9.1) 11 5.9 (3.0–10.4) 32 5.8 (4.0–8.1)
Sinus congestion 5 2.7 (0.9–6.2) 4 2.2 (0.6–5.5) 2 1.1 (0.1–3.9) 11 2.0 (1.0–3.5)
Group A = gD2-AS04 vaccine lot AHS1020A2; Group B = gD2-AS04 vaccine lot AHS1021A2; Group C = gD2-AS04 vaccine lot AHS1022A2.
Total = data from the three treatment groups pooled.
N = number of subjects
n/% = number/percentage of subjects reporting the symptom at least once
95% CI = 95% conﬁdence interval.
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pregnancy occurred during the study.4. Discussion
The present study was designed to assess the consistency of the
immune response elicited by three different commercial scale vac-
cine production lots in participants representing the target popula-
tion of the vaccine. Demonstration of lot-to-lot consistency iscritical in the development of a vaccine [17,18]. The main objective
of this trial was achieved: the two-sided 90% CIs for each GMT ratio
comparing groups receiving the different vaccine lots were within
the [0.67; 1.5] interval deﬁning lot-to-lot consistency.
All vaccine lots induced a strong immune response that per-
sisted up to the end of the trial. All subjects in the three gD2-
AS04 vaccine lot groups were seropositive for anti-gD antibodies
after the second dose and remained so through the end of the
study. Analysis of HSV-2 neutralizing antibodies also indicated
seropositivity rates >90% at each post-vaccination time point (after
G. Leroux-Roels et al. / Trials in Vaccinology 2 (2013) 10–18 17the second and the third vaccine dose and at month 12). These re-
sults in adolescent girls aged 10–17 years are consistent with those
previously observed in adult women [16,19]. Furthermore, the
administration of the third vaccine dose was followed by a robust
increase in GMT levels followed by a decrease in antibody levels
over the next 6 months.
The observed proﬁle of the GMT levels, both for the anti-gD
antibodies and neutralizing antibodies in all study groups, was
consistent with previous ﬁndings in adults [16,19]. The magni-
tude of the immune response after the third vaccine dose was
higher compared to that previously reported in HSV-1 and
HSV-2 seronegative 18–30-year-old women included in the
HERPEVAC trial [19]. In that trial (in which 8323 women were
randomized to receive the same HSV-2 vaccine at the same dose
as in the study presented here or the control vaccine Havrix™),
anti-gD GMTs at month 7 were 6809 EL.U/ml and HSV neutraliz-
ing antibody levels were 29 ED90. The difference in these levels
could be explained by differences in the age of participants: ado-
lescents in the present study and adults in the HERPEVAC trial.
Other clinical trials have shown higher immunogenicity of vac-
cines in younger age groups. For example, administration of
three doses of HPV-16/18 AS04-adjuvanted vaccine (Cervarix)
in 10–14 years old girls induced 2-fold higher GMTs for antibod-
ies to HPV-16 and -18 VLPs compared with 15–25 years old
young women [25]. Another explanation for the difference in
the magnitude of the immune responses could be methodologi-
cal differences in the assays used to determine anti-gD and anti-
HSV neutralizing antibody titers.
One of the secondary objectives of this trial was to evaluate the
safety of the gD2-AS04 candidate vaccine in all treatment groups.
The safety data suggest that the three commercial scale production
lots of gD2-AS04 vaccine have similar and acceptable overall reac-
togenicity proﬁles. Solicited symptoms after each dose and overall
were most commonly local (injection site).
Our study has several limitations. The pre-speciﬁed lot-to-lot
consistency criteria for the present study did not reach current
standards based on 95% CI; however, the study sample size
was not planned for reaching consistency with 95% CI. According
to a post-hoc analysis based on 95% CI, failure was borderline,
with a lower limit of the 95% CI of 0.66 (below the pre-deﬁned
0.67 margin). This study was conducted in accordance with
industry standards that were in place at time of study initiation,
which supported the analysis of lot-to-lot consistency to be
based on 90% CIs. Subsequent to this study, consistency analyses
based on 95% CIs became more widely used. GlaxoSmithKline,
therefore, proactively conducted a post-hoc analysis using 95%
CIs in order to support the primary analysis. However, the study
sample size was not sufﬁcient to meet the lot-to-lot equivalence
criteria with 95% CIs. Another limitation of this study was the
high rate of exclusions from the ATP cohort for immunogenicity.
A total of 242 (43.7%) subjects were not eligible for inclusion in
this cohort. Since this was more than 5% of enrolled subjects,
and as stated in the protocol, a supplemental immunogenicity
analysis on the TVC was performed (data not shown). The results
of the TVC analysis were consistent with those obtained for par-
ticipants eligible for inclusion in the ATP cohort for immunoge-
nicity; thus it is unlikely that the results of this study were
affected by the number of exclusions. A further limitation of
the study was the absence of a control group for comparison
of immunogenicity and safety data.
In conclusion, this study demonstrated the lot-to-lot consis-
tency of three different commercial scale production lots of the
herpes simplex candidate vaccine. The vaccine was immunogenic
and was shown to have a clinically acceptable safety proﬁle
when administered in HSV-1 and HSV-2 seronegative girls 10–
17 years of age. The development of this gD2-AS04 candidatevaccine was stopped due to lack of efﬁcacy [19]. However, newer
candidate vaccines based at least partially on immune responses
to HSV gD are currently under development and questions
regarding the mechanism underlying the failure of previous
gD-based candidate vaccines remain. Data such as those pre-
sented here may have important implications for future vaccine
development activities.
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